{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T15:11:44Z","timestamp":1762355504194,"version":"build-2065373602"},"reference-count":0,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T00:00:00Z","timestamp":1529539200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["CA A Cancer J Clinicians"],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>\n                    <jats:list list-type=\"bullet\">\n                      <jats:list-item>\n                        <jats:p>Approximately 20% of patients with FL relapse within 2 years of diagnosis with decreasing sensitivity to treatment.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>Allo\u2010HCT is more effective in patients who are in earlier phases of the disease.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>Autologous hematopoietic cell transplantation should be considered as an option for high\u2010risk patients who experience failure of chemoimmunotherapy after initial lines of therapy.<\/jats:p>\n                      <\/jats:list-item>\n                    <\/jats:list>\n                  <\/jats:p>","DOI":"10.3322\/caac.21426","type":"journal-article","created":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T09:02:57Z","timestamp":1529571777000},"page":"235-236","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient selection and timing of allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma"],"prefix":"10.3322","volume":"68","author":[{"given":"Mike","family":"Fillon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,6,21]]},"container-title":["CA: A Cancer Journal for Clinicians"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.3322%2Fcaac.21426","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.3322\/caac.21426","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T15:04:57Z","timestamp":1762355097000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.3322\/caac.21426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,21]]},"references-count":0,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.3322\/caac.21426"],"URL":"https:\/\/doi.org\/10.3322\/caac.21426","archive":["Portico"],"relation":{},"ISSN":["0007-9235","1542-4863"],"issn-type":[{"type":"print","value":"0007-9235"},{"type":"electronic","value":"1542-4863"}],"subject":[],"published":{"date-parts":[[2018,6,21]]},"assertion":[{"value":"2018-06-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}